Compare CVM & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVM | JSPR |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 43.7M |
| IPO Year | 1987 | N/A |
| Metric | CVM | JSPR |
|---|---|---|
| Price | $5.29 | $1.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $18.13 |
| AVG Volume (30 Days) | 80.6K | ★ 974.9K |
| Earning Date | 02-13-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.98 | $1.39 |
| 52 Week High | $20.41 | $7.19 |
| Indicator | CVM | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 40.28 |
| Support Level | $4.90 | $1.46 |
| Resistance Level | $6.75 | $1.66 |
| Average True Range (ATR) | 0.64 | 0.10 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 21.62 | 4.65 |
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.